Become a member
Quick Registration
Full Registration Benefits -
Free Homepages for Doctors
Free Homepages for Hospitals
Free Homepages for Medical Conference
Free Homepages for NGO's
Personal Health Record Creation
Access to all Medical Slides
Access to all Jobs & Products Sale
| Disease Info Index | ||||||||||||||||||||||||||
|
|
Gaucher’s Disease
Drugs For Gaucher’s Disease
Page Options
Gaucher’s Disease - Causes - Symptoms - Complications - Diagnosis - Treatment - Prognosis - FAQs
4.84
/5
| |||
About |
|||
Text 
|
Children with the infantile form of the disease usually die within a year, but those who develop the disease later in life may survive for many years. The disease is most common among Ashkenazi (Eastern European) Jews.  Type 1 is a chronic form and is the most common one. Type 2 is the infantile form usually causes death in the first year of life. Type 3 is a juvenile form that can begin at any time during childhood. Deposition of the fatty substances can occur in liver, spleen, lungs, bone marrow and, less commonly, brain. This can affect the normal functioning of the body, cause organ enlargement and bone pain. The disease can occur at any age. Treatment involves enzyme replacement. Causes and Risk Factors of Gaucher’s disease Causes Gaucher’s disease arises due the lack of an enzyme called glucocerebrosidase. This enzyme normally breaks down fatty substances (lipids) called glucocerebrosides. The deficiency of the enzyme hence leads to the accumulation of lipids in different organs and tissues. The disease arises due to genetic mutations. More than 300 genetic mutations have been found to be associated with Gaucher’s disease. The disease is an inherited one that follows a pattern called autosomal recessive, i.e. both parents must be carriers of the genetic mutation that causes Gaucher’s disease for their child to develop the condition.  The risk of developing Gaucher’s disease or being a carrier increases if there is a family history of any type of Gaucher’s disease. People of Eastern or Central European Jewish (Ashkenazi) ancestry are at high risk of having type 1 Gaucher’s disease or being a carrier. Types 2 and 3 can occur in any ethnic group. |
Latest Publication and Research on Gaucher’s Disease - Updated on 04/18/2013.
Loss of ß-Glucocerebrosidase Activity Does Not Affect Alpha-Synuclein Levels or Lysosomal Function in Neuronal Cells. - Published by PubMed
[Pregnancy in Gaucher disease.] - Published by PubMed
Glucocerebrosidase inhibitors for the treatment of Gaucher disease. - Published by PubMed
Effects of imiglucerase on the growth and metabolism of Gaucher disease type I patients: a systematic review. - Published by PubMed
Screening of high-risk Gaucher disease patients using dried blood spots techniques. - Published by PubMed
Loss of ß-Glucocerebrosidase Activity Does Not Affect Alpha-Synuclein Levels or Lysosomal Function in Neuronal Cells. - Published by PubMed
[Pregnancy in Gaucher disease.] - Published by PubMed
Glucocerebrosidase inhibitors for the treatment of Gaucher disease. - Published by PubMed
Effects of imiglucerase on the growth and metabolism of Gaucher disease type I patients: a systematic review. - Published by PubMed
Screening of high-risk Gaucher disease patients using dried blood spots techniques. - Published by PubMed
|
|
|
| Share it! |  |
 |
 |
 |
 |
 |
 |
Related Links
Genetic Testing of Diseases
Genetic testing helps to confirm a genetic condition in an individual and involves q complex laboratory ...
Birth Defect - Structural Defects
A structural birth defect means that a specific body part is missing or mal-formed during the embryonic ...
Potential Treatment for Gaucher's Disease
A mechanism that enables a potential treatment for Gaucher's disease and other lysosomal storage diseases has been described by scientists at ...
Comment & Contribute
